Finance

Lists
PGEN:NASDAQ
Precigen Inc
$6.68
-1.76%
(-0.12) 1D
$6.60
-1.18% (-0.079)
After hours
Closed: Sep 10, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PGEN...
Open
$6.70
High
$6.73
Low
$6.54
Mkt. cap
2.39B
Avg. vol.
5.36M
Volume
182.00
52-wk high
$7.72
52-wk low
$2.99
EPS
-$1.10
Beta
1.02
Shares outstanding
358.04M
No. of employees
160
Open
$6.70
High
$6.73
Low
$6.54
Mkt. cap
2.39B
Avg. vol.
5.36M
Volume
182.00
52-wk high
$7.72
52-wk low
$2.99
EPS
-$1.10
Beta
1.02
Shares outstanding
358.04M
No. of employees
160
News stories
From web sources and news partners
Profile
Precigen, Inc. is an American biotechnology company. Its president and CEO is Helen Sabzevari. Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells. Wikipedia
About Precigen Inc
CEOHelen Sabzevari
Employees160
FoundedMay 21, 1998
Headquarters-
SectorBiotechnology
Websiteprecigen.com
Analyst ratings
Based on 1 analyst giving stock ratings to PGEN in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for PGEN in the last 3 months
Highest
Current $6.68
$18.00 (+169.46%)
Average
$18.00 (+169.46%)
Lowest
$18.00 (+169.46%)
Analyst
Recommendation
Action
Price target
Projected
Date
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
$18.00
+169.5%
08/05/2026
Jason Butler
Citizens JMP
Buy
Maintained
$11.00
+64.7%
05/14/2026
Last report
Aug 4, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.05 /
0.00%miss
Revenue / Est. (USD)
54.98M / 27.83M
+97.53%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.92M
4.56M
23.25M
54.98M
Cost of goods sold
13.41M
8.59M
8.20M
10.09M
Cost of revenue
13.41M
8.59M
8.20M
10.09M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
23.99M
17.64M
21.05M
22.25M
Operating expense
23.99M
17.64M
21.05M
22.25M
Total operating expenses
37.40M
26.23M
29.25M
32.34M
Operating income
-34.48M
-21.67M
-5.99M
22.64M
Other non operating income
-111.50M
60.00K
290.00K
16.00K
EBT including unusual items
-146.34M
-23.50M
-7.93M
20.07M
EBT excluding unusual items
-146.34M
-23.50M
-7.93M
20.07M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-146.34M
-23.50M
-7.93M
20.07M
Net profit margin
-5,008.35%
-514.85%
-34.10%
36.51%
Earnings per share
-
-
-
-
Interest and investment income
534.00K
1.07M
683.00K
366.00K
Interest expense
-902.00K
-2.96M
-2.91M
-2.95M
Net interest expenses
-368.00K
-1.90M
-2.22M
-2.59M
Depreciation and amortization charges
-
-
-
-
EBITDA
-33.68M
-20.53M
-4.90M
23.74M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps